Optiscan Imaging Limited announced submission of its FDA (United States Food and Drug Administration) Pre-Market Notification (510(k)) application for the InVivage® device intended for oral tissue imaging. InVivage® is a next generation, non-invasive, instantaneous form of oral imaging, targeting the severe health consequences of late-stage diagnosis of oral cancers and precancerous lesions. The technology platform enables real-time, non-destructive, 3D, in-vivo imaging at the sub-cellular level which aims to provide physicians, surgeons and pathologists with high resolution microscopic images intraoperatively that can be used to assist with diagnosis and treatment of various oral pathologies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.089 AUD | +4.71% | +8.54% | +5.95% |
Mar. 21 | Optiscan Imaging Receives More Than AU$670,000 as R&D Tax Rebate | MT |
Feb. 22 | Optiscan Imaging Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+5.95% | 46.58M | |
+8.69% | 220B | |
+6.69% | 183B | |
+10.90% | 133B | |
+25.41% | 107B | |
-0.72% | 63.05B | |
+12.72% | 51.74B | |
+3.96% | 50.47B | |
+0.40% | 40.91B | |
+15.03% | 40.59B |
- Stock Market
- Equities
- OIL Stock
- News Optiscan Imaging Limited
- Optiscan Submits FDA 510(k) Application for InVivage Device